Taken together, our data suggest that omentin levels are increased to compensate for vascular damage and/or atherogenesis due to accumulation of CVD risk factors in T2D patients with increased adiponectin levels. The gene discussed is ADIPOQ; the disease is type 2 diabetes mellitus.